Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 85
Selected: 0
NCT IDTitle
NCT05082259ASTEROID: A Trial of ASTX660 in Combination With Pembrolizumab
NCT03019003Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
NCT00006047Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
NCT04466514A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
NCT00453193Alemtuzumab and Pentostatin In T-cell Neoplasms
NCT01896856Phase I/II Study of SGI-110 With Irinotecan Versus Regorafenib or TAS-102 in Metastatic Colorectal Cancer
NCT01685268A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
NCT01145989A Study of AT9283 in Patients With Relapsed or Refractory Multiple Myeloma
NCT00506922Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT
NCT05245682Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
NCT00878423Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors
NCT00043381Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
NCT00005877Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
NCT01696032SGI-110 in Combination With Carboplatin in Ovarian Cancer
NCT02103478Pharmacokinetic Guided Dose Escalation and Dose Confirmation With Oral Decitabine and Oral Cytidine Deaminase Inhibitor (CDAi) in Patients With Myelodysplastic Syndromes (MDS)
NCT01712217A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib
NCT00005876Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
NCT00005873Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00005874Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
NCT00504205MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
NCT04013880ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT04411030A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
NCT04250246A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1
NCT06802146Early Intervention in High Risk CCUS
NCT00005871Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
NCT03220477Pembrolizumab (Immunotherapy Drug) in Combination With Guadecitabine and Mocetinostat (Epigenetic Drugs) for Patients With Advanced Lung Cancer.
NCT06297629A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
NCT00005869Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT00005870Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
NCT01752933SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
NCT01239108Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias
NCT00848601Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma
NCT00571662Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant
NCT00522990Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias
NCT01294202A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
NCT00894894Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies
NCT03813186Effect of Food on Blood Levels of ASTX727
NCT01357395A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
NCT03576963Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
NCT05360160A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
NCT04953923Thorough QT Assessment of Cedazuridine in Healthy Subjects
NCT00541034Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
NCT05007873ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
NCT01627054A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia
NCT05456269A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
NCT03306264Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
NCT00443976Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma
NCT00113113Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT03075826A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms